Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study

Fig. 2

Treatment-related toxicities according to health care systems (university- versus community-based health care system) after first cycle (a) and second cycle (b) of topotecan and cyclophosphamide containing induction therapy . Notes: Graphs are presented as number (%). p-value was obtained from Fisher’s exact test, and p < 0.05 is statistically significant (*)

Back to article page
\